Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Uncontrolled non-heartbeating donors (types I–II) with normothermic recirculat...
Journal Information
Vol. 39. Issue 7.
Pages 429-434 (September 2015)
Share
Share
Download PDF
More article options
ePub
Visits
53
Vol. 39. Issue 7.
Pages 429-434 (September 2015)
Original article
DOI: 10.1016/j.acuroe.2015.06.007
Uncontrolled non-heartbeating donors (types I–II) with normothermic recirculation vs. heartbeating donors: Evaluation of functional results and survival
Donantes en asistolia no controlada (tipos I-II) con recirculación normotérmica versus donantes en muerte cerebral: evaluación de resultados funcionales y supervivencia
Visits
...
N. Miranda-Utreraa, J. Medina-Poloa,
Corresponding author
josemedinapolo@movistar.es

Corresponding author.
, M. Pamplona-Casamayora, J.B. Passas-Martíneza, A. Rodríguez-Antolína, F. de la Rosa Kehrmanna, J.M. Duarte-Ojedaa, A. Tejido-Sáncheza, F. Villacampa Aubáa, A. Andrés Belmonteb
a Servicio de Urología, Hospital Universitario 12 de Octubre, Madrid, Spain
b Servicio de Nefrología y Coordinación de Trasplantes, Hospital Universitario 12 de Octubre, Madrid, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (4)
Table 1. Analysis of pretransplant characteristics for asystolic donors and brain-dead organ donors.
Table 2. Results after kidney transplantation in asystolic donors and brain-dead donors.
Table 3. Binary logistic regression analysis evaluating for both groups if the presence of DGF is related to pretransplant characteristics.
Table 4. Review of results, a selection of series of asystolic donation using different types of donors and compared to the results of our center.
Show moreShow less
Abstract
Objective

Non-heartbeating donors (NHBD) are an alternative to heartbeating donors (HBD). Our objective was to compare functional results and kidney survival from NHBDs and HBDs.

Material and methods

A retrospective study comparing the results of 236 normothermically preserved kidneys from type I and type II NHBDs with the results of 250 from HBDs that were transplanted in our center between 2005 and 2012. Homogeneity between groups was tested and we evaluated the presence of delayed graft function (DGF) associated with pretransplant variables of the donor and recipient.

Results

Both groups show homogeneity in pretransplant characteristics in terms of: age, HLA incompatibilities, and recipient hemodialysis time. Average follow-up time was 33 months (range 0–87) for NHBDs and 38 months (range 0–90) for HBDs. 5.5% of NHBDs showed primary non-function (PNF) vs. 4% of HBDs (p=0.42) and 80.9% of DGF vs. 46.8% of HBDs (p<0.001). At the end of the follow-up, there were no statistically significant differences in the survival of grafts (92.8% for NHBD vs. 93.6% for HBD, p=0.71) and recipients (99.1% NHBD vs. 98.6% HBD, p=0.28).

Conclusions

Although the DGF percentage was greater for NHBDs, final creatinine as well as graft and recipient survival were similar for both groups. Therefore, in our experience, kidneys from NHBDs have similar results to those from HBDs and are an excellent source of organs for transplantation.

Keywords:
Donation after the circulatory determination of death (DCDD)
Brain-dead donors (BDD)
Primary non-function
Normothermia
Delayed graft function
Graft survival
Renal transplant
Resumen
Objetivo

El donante en asistolia (DA) es una alternativa al donante en muerte cerebral (DMC). Nuestro objetivo es comparar los resultados funcionales y la supervivencia de riñones procedentes de DA y DMC.

Material y métodos

Realizamos un estudio retrospectivo comparando los resultados de 236 riñones de DA tipos I y II preservados en normotermia con 250 procedentes de DMC, trasplantados en nuestro centro entre 2005 y 2012. Se comprueba la homogeneidad entre grupos y evaluamos si la presencia de retraso en la función del injerto (RFI) de asocia a las variables pretrasplante de donante y receptor.

Resultados

Ambos grupos muestran homogeneidad en las características pretrasplante en cuanto a: edad, incompatibilidades HLA, tiempo del receptor en hemodiálisis. El tiempo medio de seguimiento es de 33 meses (rango 0–87) los DA y 38 meses (rango 0-90) para DMC. Los DA mostraron un 5,5% de no función primaria (NFP) frente a un 4% en los DMC (p=0,42) y un 80,9% de RFI frente a un 46,8% de los DMC (p<0,001). Al final del seguimiento, no hubo diferencias estadísticamente significativas en la supervivencia del injerto (92,8% DA vs. 93,6% DMC, p=0,71) y receptores (99,1% DA vs. 98,6% DMC, p=0,28).

Conclusiones

Aunque el porcentaje de RFI es mayor para los DA, tanto la creatinina final como la supervivencia del injerto y el receptor son similares para ambos grupos. Por tanto, en nuestra experiencia los riñones procedentes de DA tienen resultados similares a aquellos de DMC y constituyen una excelente fuente de órganos para trasplante.

Palabras clave:
Donación en asistolia
Donación en muerte cerebral
No función primaria
Normotermia
Retraso en la función de injerto
Supervivencia del injerto
Trasplante renal

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 19,34 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.